{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:15Z","timestamp":1788243375288,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2130,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1111\/j.1600-0404.2009.01218.x","type":"journal-article","created":{"date-parts":[[2009,10,9]],"date-time":"2009-10-09T02:40:01Z","timestamp":1255056001000},"page":"281-287","source":"Crossref","is-referenced-by-count":151,"title":["Efficacy and safety of 800 and 1200\u2003mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures"],"prefix":"10.1155","volume":"120","author":[{"given":"A.","family":"Gil-Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lopes-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BIA-2093-303 Investigators Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB1","volume-title":"The treatment of epilepsy","author":"Almeida","year":"2009"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"J Med Chem"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/0126839-200809060-00007","article-title":"Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers","volume":"9","author":"Fontes-ribeiro","year":"2008","journal-title":"Drugs RD"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00126839-200506040-00002","article-title":"Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093)","volume":"6","author":"Maia","year":"2005","journal-title":"Drugs RD"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Falcao","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","article-title":"Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate","volume":"46","author":"Maia","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"International League against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2009.01218.x-BIB12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2009.01218.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2009.01218.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:42:49Z","timestamp":1671540169000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2009.01218.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2009.01218.x","relation":{},"ISSN":["0001-6314","1600-0404"],"issn-type":[{"value":"0001-6314","type":"print"},{"value":"1600-0404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}